Table 1.
Main characters of studies included in this meta-analysis.
| Author | Year | Country | Ethnicity | Cancer type | Genotyping method | Case/n | Control/n | P for HWE | NOS scores |
|---|---|---|---|---|---|---|---|---|---|
| Amirzargar et al. [18] | 2005 | Iran | Caucasian | Leukemia | PCR-SSP | 30 | 40 | P < 0.05 | 6 |
| Chang et al. [19] | 2015 | China | Asian | Lung cancer | PCR-RFLP | 358 | 716 | P < 0.05 | 8 |
| Chu et al. [39] | 2012 | China | Asian | Bladder cancer | TaqMan | 816 | 1140 | 0.323 | 7 |
| Chu et al. [38] | 2012 | China | Asian | Renal cell carcinoma | TaqMan | 620 | 623 | 0.079 | 7 |
| Crusius et al. [26] | 2008 | Netherlands | Caucasian | Gastric cancer | PCR-RFLP | 242 | 1154 | 0.603 | 7 |
| El-Omar et al.[20] | 2003 | Scotland | Mixed | Esophageal cancer | PCR-ARMS | 90 | 209 | P < 0.05 | 6 |
| El-Omar et al. [20] | 2003 | Scotland | Mixed | Gastric cancer | PCR-ARMS | 122 | 209 | P < 0.05 | 7 |
| Gaur et al. [27] | 2011 | India | Caucasian | Oral carcinoma | PCR-RFLP | 140 | 120 | 0.095 | 8 |
| Gu and Shen [28] | 2014 | China | Asian | Lung cancer | TaqMan | 500 | 500 | 0.348 | 7 |
| Lai et al. [29] | 2005 | China | Asian | Gastric cancer | PCR-RFLP | 123 | 162 | 0.698 | 7 |
| Li et al. [21] | 2012 | China | Asian | Lung cancer | PCR-RFLP | 1072 | 1126 | P < 0.05 | 7 |
| Liang et al. [30] | 2010 | China | Asian | Gastric cancer | PCR | 238 | 112 | 0.118 | 7 |
| Lu et al. [31] | 2014 | China | Asian | Hepatocellular cancer | PCR | 154 | 170 | 0.549 | 7 |
| Olson et al. [22] | 2007 | USA | Mixed | Prostate cancer | PCR-RFLP | 149 | 128 | P < 0.05 | 8 |
| Pan et al. [32] | 2014 | China | Asian | Gastric cancer | PCR | 308 | 307 | 0.389 | 7 |
| Saxena et al. [23] | 2014 | India | Caucasian | Hepatocellular cancer | TaqMan | 59 | 153 | P < 0.05 | 7 |
| Tsai et al. [40] | 2005 | China | Asian | Oral carcinoma | PCR-RFLP | 130 | 105 | 0.741 | 7 |
| Yang et al. [33] | 2014 | China | Asian | Oral carcinoma | PCR-RFLP | 463 | 623 | 0.233 | 7 |
| Zambon et al. [34] | 2008 | Italy | Caucasian | Gastric cancer | TaqMan | 40 | 64 | 0.800 | 7 |
| Ando et al. [35] | 2009 | Japan | Asian | Gastric cancer | TaqMan | 330 | 190 | 0.248 | 7 |
| Kesarwani et al. [24] | 2008 | India | Asian | Prostate cancer | PCR-ARMS | 200 | 200 | P < 0.05 | 7 |
| Denny et al. [36] | 2018 | Spanish | Caucasian | Gastric cancer | PCR-RFLP | 15 | 20 | 0.814 | 8 |
| Tan et al. [37] | 2019 | China | Asian | Lung cancer | MASSARRAY | 199 | 266 | 0.195 | 7 |
| Keith et al. [41] | 2018 | USA | Caucasian | Lung cancer | TaqMan | 616 | 616 | 0.338 | 9 |
| Cozar et al. [25] | 2007 | Spain | Caucasian | Renal cell carcinoma | RCR-RFLP | 127 | 174 | 0.844 | 7 |
P for HWE: P value for Hardy–Weinberg equilibrium; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; ARMS: amplification refractory mutation system; SSP: sequence specific primers.